Odonate therapeutics, inc. (ODT)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating expenses:
Research and development

105,350

104,034

104,978

101,548

92,119

79,948

66,191

53,650

39,908

27,902

0

0

0

General and administrative

11,179

10,896

10,720

11,014

10,986

10,816

10,842

9,128

6,991

4,842

0

0

0

Total operating expenses

116,529

114,930

115,698

112,562

103,105

90,764

77,033

62,778

46,899

32,744

0

0

0

Loss from operations

-116,529

-114,930

-115,698

-112,562

-103,105

-90,764

0

0

0

-

0

0

-

Interest income

3,186

3,105

2,948

2,201

0

-

0

0

-

-

-

-

-

Net loss

-113,343

-111,825

-112,737

-110,036

-100,724

-88,960

-75,943

-62,389

-46,899

-32,744

0

0

0

Net loss per share:
Basic and diluted

-0.99

-0.86

-0.88

-1.15

-1.16

-1.18

-0.98

-0.79

-0.69

-1.00

-0.74

-0.31

-0.26

Weighted-average shares outstanding:
Basic and diluted

30,610

30,657

30,268

24,893

24,682

24,641

24,453

24,402

24,351

19,435

14,036

12,740

10,464